Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer
- 16 January 2024
- journal article
- research article
- Published by SAGE Publications in Thyroid®
- Vol. 34 (4) , 484-495
Abstract
Background: Anaplastic thyroid cancer (ATC) is highly aggressive and has very limited treatment options. Recent studies suggest that cancer stem cell (CSC) activity in ATC could underlie this recurrence and resistance to treatment. The recent approval by the U.S. Food and Drug Administration of the combined treatment of BRAF and MEK inhibitors for ATC patients has shown some efficacy in patients harboring the BRAFV600E mutation. However, it was unknown whether the combined treatment could affect the CSC activity. This study explores the effects of the BRAF and MEK inhibitors on CSC activity in human ATC cells. Methods: Using three human ATC cells, THJ-11T (11T), THJ-16T (16T) and 8505C cells, we evaluated the effects of dabrafenib (a BRAF kinase inhibitor), trametinib (a MEK inhibitor) or a combined treatment of the two drugs on the CSC activity by tumorsphere formation, Aldefluor assays, expression profiles of key CSC markers, immunohistochemistry, and in vivo xenograft mouse models. Furthermore, we also used confocal imaging to directly visualize the effects on drugs on CSC cells by SORE6-mCherry reporter in cultured cells and xenograft tumor cells. Results: The BRAF inhibitor, dabrafenib, had weak efficacy, while the MEK inhibitor, trametinib, showed strong efficacy in attenuating the CSC activity, as evidenced by suppression of CSC marker expression, tumorsphere formation, and Aldefluor assays. Using ATC cells expressing a flurorescent CSC SORE6 reporter, we showed reduction of CSC activity in the rank order of combined>trametinib>dabrafenib through in vitro and in vivo xenograft models. Molecular analyses showed that suppression of CSC activity by these drugs was in part mediated by attenuation of the transcription by dampening the RNA polymerase II activity. Conclusions: Our analyses demonstrated the presence of CSC in ATC cells. The inhibition of CSC activity by the MEK signaling could partially account for the efficacy of the combined treatment shown in ATC patients. However, our studies also showed that not all CSC activity was totally abolished, which may account for the recurrence observed in ATC patients. Our findings have provided new insights into the molecular basis of efficacy and limitations of these drugs in ATC patients.Keywords
This publication has 24 references indexed in Scilit:
- A Flexible Reporter System for Direct Observation and Isolation of Cancer Stem CellsStem Cell Reports, 2015
- Inhibition of Tumorigenesis by the Thyroid Hormone Receptor β in Xenograft ModelsThyroid®, 2014
- Cancer stem cell definitions and terminology: the devil is in the detailsNature Reviews Cancer, 2012
- Phosphorylation regulates human OCT4Proceedings of the National Academy of Sciences, 2012
- Detailed Molecular Fingerprinting of Four New Anaplastic Thyroid Carcinoma Cell Lines and Their Use for Verification of RhoB as a Molecular Therapeutic TargetThe Journal of Clinical Endocrinology & Metabolism, 2010
- Tumorigenic and Metastatic Activity of Human Thyroid Cancer Stem CellsCancer Research, 2010
- Identification and targeting of cancer stem cellsBioEssays, 2009
- In Vitro Identification and Characterization of CD133pos Cancer Stem-Like Cells in Anaplastic Thyroid Carcinoma Cell LinesPLOS ONE, 2008
- A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cellsNature Cell Biology, 2004
- Functional divergence of the MAP kinase pathway ERK1 and ERK2 activate specific transcription factorsFEBS Letters, 1994